Literature DB >> 26175307

Postoperative biochemical remission of serum calcitonin is the best predictive factor for recurrence-free survival of medullary thyroid cancer: a large-scale retrospective analysis over 30 years.

Kyong Yeun Jung1, Seok-Mo Kim2, Won Sang Yoo3,4, Bup-Woo Kim2, Yong Sang Lee2, Kyung Won Kim3, Kyu Eun Lee5, Jong Ju Jeong2, Kee-Hyun Nam2, Se Hoon Lee3,6, Jeong Hun Hah7, Woong Youn Chung2, Ka Hee Yi3,8, Do Joon Park3,6, Yeo-Kyu Youn5, Myung-Whun Sung7, Bo Youn Cho3,9, Cheong Soo Park2, Young Joo Park3,6, Hang-Seok Chang2.   

Abstract

CONTEXT: The increase in thyroid screening in the general population may lead to earlier detection of medullary thyroid carcinoma (MTC).
OBJECTIVE: We aimed to evaluate secular trends in clinicopathological characteristics and long-term prognosis of MTC and its prognostic factors.
DESIGN: This was a retrospective analysis from 1982 to 2012. PATIENTS: Three hundred and thirty-one patients with MTC were included and grouped based on the year of diagnosis (1982-2000, 2001-2005, 2006-2010 and 2011-2012). MEASUREMENTS: These included recurrence and mortality as well as biochemical remission (BCR) of serum calcitonin.
RESULTS: Mean tumour size (from 2·5 cm to 1·7 cm, P < 0·001) and percentage of extrathyroidal extension (from 52·0% to 26·0%, P = 0·026) decreased. The percentage of patients achieving BCR within six postoperative months (po-BCR) increased with time (from 39·6% to 76·1%, P < 0·001). The 5-year overall recurrence rate significantly decreased in 2006-2012 compared to 1982-2005 (10% vs 18%, respectively, P = 0·031), although the 5-year survival rate did not improve (92% vs 92%, P = 0·929). Failure to achieve po-BCR was the strongest predictive factor associated with recurrence (hazard ratio [HR] = 58·04, 95% CI 7·14-472·11; P < 0·001). Male gender (HR = 3·18, 95% CI 1·18-8·56; P = 0·022), tumour size >2 cm (HR = 18·33, 95% CI 2·35-143·06; P = 0·006) and distant metastasis (HR = 4·00, 95% CI 1·31-12·21; P = 0·015) were significant prognostic factors for mortality.
CONCLUSIONS: Clinicopathological characteristics and recurrence of MTC improved with time. Po-BCR was the best predictive factor for recurrence-free survival.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26175307     DOI: 10.1111/cen.12852

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  15 in total

1.  Clinicopathological Significance and Prognosis of Medullary Thyroid Microcarcinoma: A Meta-analysis.

Authors:  Jin Hwa Kim; Jung-Soo Pyo; Won Jin Cho
Journal:  World J Surg       Date:  2017-10       Impact factor: 3.352

2. 

Authors:  凡 吴; 天晗 周; 凯宁 陆; 婷 潘; 烨钦 倪; 玲倩 赵; 可成 姜; 煜 张; 定存 罗
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-12-25

3.  Risk factors for lateral cervical lymph node metastasis in medullary thyroid carcinoma.

Authors:  Fan Wu; Tianhan Zhou; Kaining Lu; Ting Pan; Yeqin Ni; Lingqian Zhao; Kecheng Jiang; Yu Zhang; Dingcun Luo
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-12-25

4.  Kinetic analysis of the growth rate of sporadic and hereditary medullary thyroid carcinoma: comparing the postoperative calcitonin-doubling rate with the hypothetical preoperative tumor volume-doubling rate.

Authors:  Minoru Kihara; Akira Miyauchi; Hiroo Masuoka; Takuya Higashiyama; Yasuhiro Ito; Akihiro Miya
Journal:  Thyroid Res       Date:  2020-07-21

Review 5.  Recent Updates on the Management of Medullary Thyroid Carcinoma.

Authors:  Bo Hyun Kim; In Joo Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2016-08-26

6.  Postoperative Neck Ultrasonography Surveillance After Thyroidectomy in Patients With Medullary Thyroid Carcinoma: A Multicenter Study.

Authors:  Hye Shin Ahn; Dong Wook Kim; Yoo Jin Lee; Chang Yoon Lee; Ji-Hoon Kim; Yoon Jung Choi; Song Lee; Inseon Ryoo; Jung Yin Huh; Jin Yong Sung; Jin Young Kwak; Hye Jin Baek
Journal:  Front Endocrinol (Lausanne)       Date:  2018-03-15       Impact factor: 5.555

Review 7.  Recent Development of Nuclear Molecular Imaging in Thyroid Cancer.

Authors:  Huiting Liu; Xiaoqin Wang; Ran Yang; Wenbing Zeng; Dong Peng; Jason Li; Hu Wang
Journal:  Biomed Res Int       Date:  2018-05-21       Impact factor: 3.411

8.  A retrospective review of the multidisciplinary management of medullary thyroid cancer: eligibility for systemic therapy.

Authors:  Georgia Geller; Janessa Laskin; Winson Y Cheung; Cheryl Ho
Journal:  Thyroid Res       Date:  2017-09-19

9.  Clinical value of color Doppler ultrasound combined with serum tumor markers for the diagnosis of medullary thyroid carcinoma.

Authors:  Xue Yang; Jinjuan Xu; Jilan Sun; Lizhi Yin; Rui Guo; Zhimei Yan
Journal:  Oncol Lett       Date:  2021-05-27       Impact factor: 2.967

10.  Combining serum calcitonin, carcinoembryonic antigen, and neuron-specific enolase to predict lateral lymph node metastasis in medullary thyroid carcinoma.

Authors:  Liuqing Ye; Xi Zhou; Jie Lu; Yanzhong Wang; Xinyou Xie; Jun Zhang
Journal:  J Clin Lab Anal       Date:  2020-03-06       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.